Screener
Solid Biosciences Inc. SLDB Internal Research And Development Expense — Research And Development Expense
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Solid Biosciences Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Solid Biosciences Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337935
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| SGT-501 | 903 | 2,223 | 2,310 | 6,689 |
| SGT-212 | 2,364 | 1,145 | 5,680 | 1,970 |
| External R&D other | 1,983 | 3,116 | 4,840 | 5,886 |
| Internal R&D expense(1) | 9,060 | 6,765 | 18,211 | 13,608 |
| External G&A expense | 6,327 | 5,279 | 11,795 | 10,156 |
| Internal G&A expense(1) | 4,734 | 3,360 | 8,600 | 6,823 |
| Other segment items(2) | 7,497 | 7,586 | 15,798 | 15,228 |
| Other income, net | (2,585) | (2,213) | (3,156) | (2,983) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Solid Biosciences Inc.'s internal research and development expense — research and development expense?
- Solid Biosciences Inc. (SLDB) reported internal research and development expense — research and development expense of $9.06M in Q2 2026.
- How has Solid Biosciences Inc.'s internal research and development expense — research and development expense changed year-over-year?
- Solid Biosciences Inc.'s internal research and development expense — research and development expense increased by 33.9% year-over-year, from $6.77M to $9.06M.
- What is the long-term trend for Solid Biosciences Inc.'s internal research and development expense — research and development expense?
- Over 2 years (2023 to 2025), Solid Biosciences Inc.'s internal research and development expense — research and development expense has grown at a 16.0% compound annual growth rate (CAGR), from $21.8M to $29.34M.
- What does internal research and development expense — research and development expense mean?
- This metric represents the total operating costs directly attributable to the internal research and development activities for specific therapeutic programs or product candidates. It captures the investment in scientific discovery, preclinical studies, and clinical trial execution required to advance the company's pipeline toward regulatory approval. Monitoring this expense provides insight into the company's commitment to innovation and the capital intensity required to sustain its drug development lifecycle.
Ask your AI about Solid Biosciences Inc.'s internal research and development expense — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude